BI-2536
-
- Application
- Inhibition (Inh)
- Purpose
- Dual Plk/BRD4 inhibitor, Destabilizes Myc
- Characteristics
- BI 2536 was originally reported as a potent (IC50's Plk1 = 0.83nM, Plk2 = 3.5nM and Plk3 = 9.0nM) and selective2 Polo-like kinase inhibitor (IC50's Plk1 = 0.83nM, Plk2 = 3.5nM and Plk3 = 9.0nM) that caused mitotic arrest and apoptosis induction in various human cancer cell lines. It was later found to be a potent inhibitor (IC50 = 100nM) of BET family member BRD4 and able to potently suppress c-Myc expression in MM.1S multiple myeloma cells. BI 2536 destabilizes N-Myc by inhibiting the deactivation of the ubiquitin E3 ligase Fbw7 by Plk1.
- Purity
- >97 %
- Chemical Name
- 4-[[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-7H-pteridin-2-yl]amino]-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide
- Formula
- C28H39N7O3
- Solubility
- Soluble in DMSO (up to 20 mg/ml) or in Ethanol (up to 25 mg/ml)
-
-
- Restrictions
- For Research Use only
-
- Format
- Powder
- Storage
- -20 °C
-
- Background
- Apoptosis inducer,Epigenetics,Cell cycle,Myc,Bromodomain,Ubiquitin/Proteasome,Cell death,Cancer,Posttranslational modification,Chromatin
- Molecular Weight
- 521.67
- CAS-No
- 755038-02-9
-